Ovarian cancer-associated antigen OC166-9 peptide-MHC complex (OC166-9 pMHC)

The target Ovarian cancer cells presenting OC166-9–like peptide–MHC complexes refers to the surface presentation of peptides derived from or mimicking the OC166-9 tumor-associated antigen on Major Histocompatibility Complex (MHC) molecules [1.2.1, 1.3.3]. OC166-9 is a specific antigen found on ovarian cancer cells, and its internal image is mimicked by the anti-idiotypic antibody 6B11 [1.3.2]. In therapeutic contexts, autologous T cells or cytokine-induced killer (CIK) cells are primed with 6B11 or its derived peptides to recognize these specific pMHC complexes [1.3.1, 1.4.1]. This recognition triggers a targeted cytotoxic immune response against the malignant cells [1.3.4]. This approach is primarily investigated for treating advanced, platinum-resistant, or recurrent ovarian cancer [1.3.2]. The specificity of the interaction is often restricted by the patient's HLA subtype, such as HLA-A*02 [1.2.1]. The development of therapies like 6B11-OCIK represents a specialized form of adoptive cell therapy designed to overcome immune tolerance in ovarian cancer patients [1.3.2, 1.4.1].

Other names

OC166-9 antigen6B11-mimicked antigenOvarian cancer-related antigen OC166-9OC166-9-like peptide-MHC complex

Adoptive immunotherapy utilizing autologous T cells or cytokine-induced killer (CIK) cells primed to recognize OC166-9-like peptides presented on MHC molecules, leading to targeted lysis of ovarian cancer cells.